Shelter Pharma Limited reported a 24.7% increase in net profit to ₹902.72 lakh for the year ended March 31, 2026, compared to ₹723.74 lakh in the previous year. Revenue from operations surged 44.4% to ₹7,313.36 lakh from ₹5,066.02 lakh in FY25. The board approved the audited standalone financial results for the half-year and full year ended March 31, 2026, at a meeting held on May 28, 2026.

The statutory auditors, Alvi & Associates, issued an audit report with an unmodified opinion on the financial results. The board also appointed CA Ismail Ibrahimhai Lakhani (M/S. I I LAKHANI & CO) as the internal auditor for the financial year 2026-27.

Financial Performance

The company’s total income for FY26 stood at ₹7,314.95 lakh, up from ₹5,066.56 lakh in the previous year. Total expenses increased to ₹6,092.48 lakh from ₹4,098.86 lakh. Profit before tax for the year rose to ₹1,222.47 lakh from ₹967.70 lakh in the prior year.

For the half-year ended March 31, 2026, the company reported a net profit of ₹452.65 lakh on revenue from operations of ₹3,984.07 lakh.

Key Financial Metrics

Utilization of Funds

The company reported that the full amount of ₹2,531.20 lakh raised through the preferential issue of convertible warrants into equity shares was utilized for working capital requirements. There was no deviation in the utilization of funds.

Shelter Pharma Ltd has announced its participation in the 12th Edition of iPHEX 2026, one of India's leading international pharmaceutical and healthcare exhibitions. The event is scheduled to take place from September 7, 2026, to September 9, 2026, at Bharat Mandapam. The exhibition is organized by the Pharmaceuticals Export Promotion Council of India with the support of the Department of Commerce, Government of India.

The company has secured an exhibition stall to showcase its pharmaceutical and healthcare product portfolio. The target audience includes domestic and international business delegates, distributors, importers, and other industry participants. This strategic move is intended to enhance the company's global visibility and brand recognition.

Strategic Objectives

Participation in iPHEX 2026 is expected to yield several strategic benefits for the company:

• Strengthen relationships with existing customers and business associates
• Explore new export opportunities and international market expansion
• Facilitate B2B interactions with overseas buyers and healthcare stakeholders

The management believes that engaging in such globally recognized industry exhibitions aligns with Shelter Pharma's long-term growth and business development strategy.

Event Details